Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert Lipitor

Executive Summary

PMCPA appeal board upholds panel's ruling that a Lipitor (atorvastatin) leavepiece and mailing disseminated in the U.K by copromoters Parke-Davis and Pfizer were misleading in their comparisons to other statin drugs. The pieces summarize data from the CURVES comparative study with other statins, and claim that Lipitor "lowers triglycerides by up to 45%," based on a 12-patient subgroup in the study receiving 80 mg daily. The materials also stated that most patients would reach their LDL-cholesterol lowering goals on 10 mg atorvastatin daily. The appeal board maintains that the pieces imply the 10 mg dose of Lipitor would lower triglycerides to the degree claimed, noting that "with no indication to the contrary, the claim in question would also be assumed to relate to the 10 mg daily dose, which was not so." The materials mislead readers as to the "degree that triglyceride levels might be lowered using starting dose of Lipitor." The highest triglyceride reduction for Lipitor in the U.K. label is 33% at a dose of 20 mg
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel